C4 Therapeutics, Inc. (CCCC)
CCCC Stock Price Chart
Explore C4 Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CCCC price movements and trends.
CCCC Company Profile
Discover essential business fundamentals and corporate details for C4 Therapeutics, Inc. (CCCC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Oct 2020
Employees
110.00
Website
https://www.c4therapeutics.comCEO
Andrew J. Hirsch
Description
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
CCCC Financial Timeline
Browse a chronological timeline of C4 Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.23, while revenue estimate is $8.20m.
Earnings released on 12 May 2026
EPS came in at -$0.20 surpassing the estimated -$0.25 by +20.20%, while revenue for the quarter reached $6.20m , beating expectations by +40.38%.
Earnings released on 26 Feb 2026
EPS came in at -$0.18 surpassing the estimated -$0.31 by +41.94%, while revenue for the quarter reached $11.02m , beating expectations by +104.20%.
Earnings released on 6 Nov 2025
EPS came in at -$0.44 falling short of the estimated -$0.41 by -8.45%, while revenue for the quarter reached $11.20m , beating expectations by +78.34%.
Earnings released on 7 Aug 2025
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.63%, while revenue for the quarter reached $6.46m , missing expectations by -1.33%.
Earnings released on 6 May 2025
EPS came in at -$0.37 surpassing the estimated -$0.48 by +22.92%, while revenue for the quarter reached $7.20m , beating expectations by +61.80%.
Earnings released on 27 Feb 2025
EPS came in at -$0.49 falling short of the estimated -$0.45 by -8.89%, while revenue for the quarter reached $5.18m , beating expectations by +1.66%.
Earnings released on 31 Oct 2024
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%, while revenue for the quarter reached $15.40m , beating expectations by +160.97%.
Earnings released on 1 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.37 by +29.73%, while revenue for the quarter reached $12.01m , beating expectations by +151.00%.
Earnings released on 8 May 2024
EPS came in at -$0.41 matching the estimated -$0.41, while revenue for the quarter reached $3.04m , missing expectations by -74.66%.
Earnings released on 21 Feb 2024
EPS came in at -$0.68 falling short of the estimated -$0.67 by -1.49%, while revenue for the quarter reached $3.27m , beating expectations by +1.91%.
Earnings released on 1 Nov 2023
EPS came in at -$0.55 surpassing the estimated -$0.65 by +15.38%, while revenue for the quarter reached $11.07m , beating expectations by +109.85%.
Earnings released on 8 Aug 2023
EPS came in at -$0.73 falling short of the estimated -$0.68 by -6.68%, while revenue for the quarter reached $2.66m , missing expectations by -58.46%.
Earnings released on 4 May 2023
EPS came in at -$0.71 surpassing the estimated -$0.78 by +8.97%, while revenue for the quarter reached $3.76m , missing expectations by -31.19%.
Earnings released on 23 Feb 2023
EPS came in at -$0.76 falling short of the estimated -$0.72 by -5.56%, while revenue for the quarter reached $2.85m , missing expectations by -71.13%.
Earnings released on 3 Nov 2022
EPS came in at -$0.65 surpassing the estimated -$0.67 by +2.99%, while revenue for the quarter reached $6.75m , missing expectations by -20.07%.
Earnings released on 4 Aug 2022
EPS came in at -$0.56 surpassing the estimated -$0.68 by +17.65%, while revenue for the quarter reached $13.80m , beating expectations by +80.69%.
Earnings released on 5 May 2022
EPS came in at -$0.65 falling short of the estimated -$0.61 by -6.56%, while revenue for the quarter reached $7.65m , missing expectations by -1.94%.
Earnings released on 24 Feb 2022
EPS came in at -$0.31 surpassing the estimated -$0.59 by +47.46%, while revenue for the quarter reached $20.08m , beating expectations by +171.02%.
Earnings released on 10 Nov 2021
EPS came in at -$0.51 surpassing the estimated -$0.60 by +15.00%, while revenue for the quarter reached $8.50m , missing expectations by -13.04%.
Earnings released on 11 Aug 2021
EPS came in at -$0.51 surpassing the estimated -$0.60 by +15.00%, while revenue for the quarter reached $9.78m , beating expectations by +62.48%.
CCCC Stock Performance
Access detailed CCCC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
